Eisai Eyes New Product Launches, Strong Growth In Asia To Offset Aricept Patent Loss
This article was originally published in PharmAsia News
Executive Summary
Preparing for patent expiry for blockbuster Alzheimer's disease drug Aricept (donepezil) in November, Eisai will step up efforts to launch new products in the fiscal year, company President Haruo Naito said during the company's Feb. 2 earnings conference call